Cost-Effectiveness of Inotersen for Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-NP) in Peru: An Illustrative Case of the Limits of the Cost-Per-QALY Framework in Rare Diseases IMPAC-FE Study

Javier Torres-Valencia, Héctor Luis Bojórquez-Castillo, Fiorella F Navarro-Vásquez, Josías Palza-Valenzuela, María Fernanda Cueva, Nancy Elena Loayza-Urcia, Ricardo Román-Carpio, Jesús Daniel Borja-Tovalino, Ana Lucía Castillo-Soto, Celso Moraes, Fernando Colugnati, José Francisco Parodi-García, Ricardo Miguel Fujita-Alarcón, Gustavo Lorenzo Moretta

Open source

DOI: 10.20944/preprints202607.0607.v1
Published: 2026-07-08
Container: Not recorded
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 60/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
cautionPublication version: Identified as a preprint; peer review and later versions may change the record. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.20944/preprints202607.0607.v1,
  title = {Cost-Effectiveness of Inotersen for Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-NP) in Peru: An Illustrative Case of the Limits of the Cost-Per-QALY Framework in Rare Diseases IMPAC-FE Study},
  author = {Javier Torres-Valencia and Héctor Luis Bojórquez-Castillo and Fiorella F Navarro-Vásquez and Josías Palza-Valenzuela and María Fernanda Cueva and Nancy Elena Loayza-Urcia and Ricardo Román-Carpio and Jesús Daniel Borja-Tovalino and Ana Lucía Castillo-Soto and Celso Moraes and Fernando Colugnati and José Francisco Parodi-García and Ricardo Miguel Fujita-Alarcón and Gustavo Lorenzo Moretta},
  year = {2026},
  doi = {10.20944/preprints202607.0607.v1},
  url = {https://doi.org/10.20944/preprints202607.0607.v1}
}

RIS

TY  - JOUR
TI  - Cost-Effectiveness of Inotersen for Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-NP) in Peru: An Illustrative Case of the Limits of the Cost-Per-QALY Framework in Rare Diseases IMPAC-FE Study
AU  - Javier Torres-Valencia
AU  - Héctor Luis Bojórquez-Castillo
AU  - Fiorella F Navarro-Vásquez
AU  - Josías Palza-Valenzuela
AU  - María Fernanda Cueva
AU  - Nancy Elena Loayza-Urcia
AU  - Ricardo Román-Carpio
AU  - Jesús Daniel Borja-Tovalino
AU  - Ana Lucía Castillo-Soto
AU  - Celso Moraes
AU  - Fernando Colugnati
AU  - José Francisco Parodi-García
AU  - Ricardo Miguel Fujita-Alarcón
AU  - Gustavo Lorenzo Moretta
PY  - 2026
DO  - 10.20944/preprints202607.0607.v1
UR  - https://doi.org/10.20944/preprints202607.0607.v1
ER  -

APA

Torres-Valencia, J., Bojórquez-Castillo, H. L., Navarro-Vásquez, F. F., Palza-Valenzuela, J., Cueva, M. F., Loayza-Urcia, N. E., Román-Carpio, R., Borja-Tovalino, J. D., Castillo-Soto, A. L., Moraes, C., Colugnati, F., Parodi-García, J. F., Fujita-Alarcón, R. M., & Moretta, G. L. (2026). Cost-Effectiveness of Inotersen for Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-NP) in Peru: An Illustrative Case of the Limits of the Cost-Per-QALY Framework in Rare Diseases IMPAC-FE Study. https://doi.org/10.20944/preprints202607.0607.v1

Source records

crossref · retrieved 2026-09-26T09:41:19.682Z